Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Gastrointestinal cancer

Which way is forward in the treatment of rectal cancer?

Nature Reviews Clinical Oncology volume 10, pages 12–13 (2013)Cite this article

Subjects

Preoperative 5-fluorouracil-based chemoradiation with optimal surgery provides very effective local control in locally advanced rectal cancer. Does adding oxaliplatin as a radiosensitizer provide any additional benefit? Is more always better?

Key Points

In standard practice there is no benefit from adding oxaliplatin as a radiosensitizer to 5-fluorouracil-based preoperative chemoradiaton in rectal cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gérard, J. P. et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.42.8771.

  2. Gérard, J. P. et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J. Clin. Oncol. 28, 1638–1644 (2010).

    Article  Google Scholar 

  3. Aschele, C. et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J. Clin. Oncol. 29, 2773–2780 (2011).

    Article  CAS  Google Scholar 

  4. Roh, M. S. et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04 [abstract]. J. Clin. Oncol. 29 (Suppl.) a3503 (2011).

    Article  Google Scholar 

  5. Rödel, C. et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 13, 679–687 (2012).

    Article  Google Scholar 

  6. Habr-Gama, A. & Perez, R. O. Non-operative management of rectal cancer after neoadjuvant chemoradiation. Br. J. Surg. 96, 125–127 (2009).

    Article  CAS  Google Scholar 

  7. Maas, M. et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J. Clin. Oncol. 29, 4633–4640 (2011).

    Article  Google Scholar 

  8. Beets-Tan, R. G. & Beets, G. L. Local staging of rectal cancer: a review of imaging. J. Magn. Reson. Imaging 33, 1012–1019 (2011).

    Article  Google Scholar 

  9. Martini, M., Vecchione, L., Siena, S., Tejpar, S. & Bardelli, A. Targeted therapies: how personal should we go? Nat. Rev. Clin. Oncol. 9, 87–97 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Maastricht University Medical Center, P. Debyelaan 25, Maastricht, 6229 HX, The Netherlands

    Rob L. H. Jansen

  2. Department of Surgery, Maastricht University Medical Center, P. Debyelaan 25, Maastricht, 6229 HX, The Netherlands

    Geerard L. Beets

Authors
  1. Rob L. H. Jansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geerard L. Beets
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Geerard L. Beets.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jansen, R., Beets, G. Which way is forward in the treatment of rectal cancer?. Nat Rev Clin Oncol 10, 12–13 (2013). https://doi.org/10.1038/nrclinonc.2012.217

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.217

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing